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j Summary: The kininogenase, tissue kallikrein (EC 3.4.21.8), has been identified in different blood vessels. The
; enzyme was mainly found in vascular smooth muscle cells. It is not known whether it is present and functionally
j active in vascular endothelial cells. The following study investigates the presence of tissue kallikrein in endothelial
l cells from human umbilical veins and pulmonary arteries. Tissue kallikrein was demonstrated in three ways:
1) by immunostaining in endothelial cells;
2) by measurement of tissue kallikrein activity using a colorimetric assay;
3) by the measurement of kinin release in intact and homogenised endothelial cells with a radioimmunoassay.
Immunostaining demonstrated the presence of tissue kallikrein in endothelial cells from human umbilical veins and
endothelial cells from human pulmonary arteries. Tissue kallikrein-like activity, measured by the degradation of D-
Val-cyclohexyl-Ala-Arg-4-nitraniline, was 3.57 ± 0.5 mU/106 endothelial cells from human umbilical veins and
7.52 ± 0.84 mU/106 endothelial cells from human pulmonary arteries. Intracellular kinin concentrations were
424 ± 83 pg/106 cells in endothelial cells from human umbilical veins and 576 ± 146 pg/106 cells in endothelial
cells from human pulmonary arteries, and they increased in a time-dependent manner after homogenisation. The
increase was abolished by aprotinin (1000 klU), an inhibitor of tissue kallikrein in both cell types. Addition of
exogenous kallikrein (5 mll) to homogenised cells led to a five fold increase of kinin concentrations after five
minutes, indicating a sufficient resource of cellular kininogen. Removal of extracellularly bound kininogen by
washing with dextran sulphate (100 mg/1) resulted in an approximately 75% reduction of the cellular kinin release.
This suggests that extracellular kininogen is the main source of endothelial kinin production. The present data
demonstrate the presence of tissue kallikrein in human endothelial cells and provide evidence for the ability of
human endothelial cells to release kinins.
Introduction blood. Presence of tissue kallikrein was shown in differ-
ent tissues and body fluids, e. g. pancreas, submandibu-
Kinins are potent vasodilators, which contribute to the \^ glands and urine (5). Although the presence of tissue
local regulation of vascular tone (l, 2). Their vasorelax- kallikrein in the endothelium has not been directly dem-
ant effect is rnediated by the release of endothelium- onstrated, several pharmacological studies using the
derived relaxing factor and prostacyclin (3, 4). Kinins bradykinin-receptor antagonist, HOB 140, and angioten-
are released from, kininogens by tissue (glandular) and sin converting enzyme inhibitors suggest the presence
Plasma kallikreins, two serine proteases of restricted of a kinin generating System in the endothelium (6-8).
Substrate specificity (5). Plasma kallikrein bound to high In the vasculature, the occurrence of tissue kallikrein-
molecular weight kininogen circulates in the human like enzyme has been described in the adventitia of the
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rat (9) and in vascular smooth muscle cells isolated from
the rat aorta (10). Saed (11) has demonstrated the pres-
ence of tissue kallikrein mRNA in rat arteries and veins
and in isolated smooth muscle cells of the rat. Kalli-
krein-like activity is present in human tissue from aorta
and renal arteries (12). Moshi and co-workers described
a kininogenase in canine myocardium and aorta, which
releases bradykinin and shows similarities with tissue
kallikrein (13). However, most investigators attribute tis-
sue kallikrein activity to the vascular smooth muscle
cells, but not to endothelial cells, although the vascular
endothelium seems to be one of the main targets of kinin
action (l —4). Therefore we investigated the presence of
tissue kallikrein in cultured human endothelial cells by
three different methods: immunostaining, measurement
of enzyme activity, and measurement of kinin release.
Materials and Methods
Cell culture
Human umbilical vein endothelial cells were prepared according
to the method of Jaffe (14) s previously described (15). For the
preparation of human pulmonary artery endothelial cells, Segments
of human pulmonary arteries (1.5—3.5 cm?) were incubated in 2 g/l
collagenase (Roth, Karlsruhe, Germany) for 30 minutes at 37 °C.
The segments were then rinsed with Medium 199 containing fetal
calf serum, volume fraction 0.2 (Gibco-BRL, Berlin, Germany),
and the detached cells were collected. The cell Suspension was
pelleted and seeded into a 35 mm dish (Falcon, Heidelberg, Ger-
many) coated with 2 g/l gelatine (Sigma, Deisenhofen, Germany)
and incubated in culture medium at 37 °C and 5% CO2- The culture
conditions for endothelial cells from human umbilical veins and
endothelial cells from human pulmonary arteries were similar. The
culture medium contained Medium 199, fetal calf serum (volume
fraction 0.2), l O5 U/l penicillin, 100 mg/1 streptomycin, 10 mmol/1
HEPES (all Sigma), 0.2 mol/11-glutamine (Seromed, Berlin, Ger^
many), and 10 μg/l endothelial cell growth factor (Boehringer,
Mannheim, Germany). All experiments were performed with cells
of the second passage. The purity and identity of the endothelial
cultures was determined by measuring factor VIII related antigen,
using a specific antibody (Dako, Hamburg, Germany), and by mea-
suring the uptake of fluorescence conjugated-low density lipo^
protein in confluent monolayers (Paesel & Lorei, Mainz, Germany)
(16). Endothelial cells were counted using a haemocytometer.
phosphoramidon (10 nmol/1) and lisinopril .(ΓμηΐοΙ/1, ICI, Ger-
many). Confluent monolayers were washed twice with phosphate^
buffered saline, incubation medium was added, and the cells were
incubated at 37 °C. After 10 minutes, l hour and 4 hours, aliquots
of 0.2 ml were taken, frozen in liquid nitrogen, and stored at
-70 °C until measurement of kinin concentrations by RIA.
• r
Kinin release in endothelial cell hornogenates
All experiments were done in 2 ml incubation medium. Confluent
monolayers were washed twice with phosphate-buffered saline.
Thereafter, the incubation medium was added and the cultures were
allowed to equilibrate for 15 minutes. The eells were then scraped
off the culture dish and homogeriised by sonication s described
above. Aliquots of 0.2 ml were taken immediately aftef hpmogenis-
ation and after 5 and 30 minutes. Aliquots were mixed with 0.2 ml
Tris-buffer (0.2 mol/1 Tris, 0.01 mol/1 EDTA, pH 7.4, Serva AG,
Heidelberg, Germany) on ice, frozen in liquid nitrogen, and stored
at -^70 °C. Parallel experiments were performed in the presence of
1000 klU/dish aprotinin (Bayer AG, Leverkusen, Germany), which
was added 15 minutes prior to homogenisation. In a second set of
experiments, confluent cell monolayers were washed twice with
dextran sulphate (100 mg/1, Sigma) for 4 minutes at room tempera-
ture. Then the cells were incubated with the incubation medium
and bradykinin release was measured s described above. To some
cell homogenates, 0.5 or 5 U/l porcine tissue kallikrein (Sigma)
was added, and aliquots for kinin determination were taken at 5,
30 and 60 minutes afterwards.
Immunostaining
Endothelial cells were placed in phosphate-buffered saline contain-
ing 10 g/l bovine serum. albumin (Sigma). Cytocentrifugal speci^
mens containing 2 X l O5 endothelial cells per slide were prepared \
using a Cytospin 2 (Shandon Southern Prod. Ltd., Runcorn, °
Cheshire, UK) at 150 g for 5 minutes. All cytocentrifuge s des
were stained by the alkaline phosphatase anti-alkaline phosphatase
method described by Cordeil (17). The fixed cells were stained
with an anti-human tissue kallikrein antiserum (dilutiori l: 1000)
(18) or an antibody against factor VIII related antigen (dilution
l : 100, Dako), which was used s positive control. Incubation with
a preimmune antiserum (instead of kallikrein antibody) was per^
formed s a negative control. After immunostaining, slides were
counterstained with Mayer's acid haematoxylin. The number of
positive cells was estimated by evaluation of 5 mieroscopic power-
flelds of each specimen (magnification X 200; endothelial cells
from human umbilical Veins: n = 5, endothelial cells from human
pulmonary arteries: n = 3).
Measurement of t issue kallikrein activity in
endothelial cells
Confluent monolayers of endothelial cells from human umbilical
veins and endothelial cells from human pulmonary arteries in 35
mm dishes were washed twice with phosphate-buffered saline
(Gibco-BRL), scraped off the dish with a rubber policeman, sus-
pended in 0.5 ml Tris buffer (0.1 mol/1, pH 7.4), containing l ml/l
Tween 20 (Serva, Heidelberg, Germany), then sonicated for 5 se-
conds (20% Output energy) with a Sonifier B-12 (Branson Sonic
Power Co., Danbury, Co., USA) on ice. Samples of the cell homo-
genate were assayed immediately for tissue kallikrein activity.
Kinin release in endothelial cell supernatants
All experiments were done in 1.5 ml serum-free incubation me-
dium to avoid interference of the serum with the bradykinin RIA.8
The serum-free medium contained RPMI 1640 (Gibco-BRL), 10
mmol/1 HEPES (Sigma), antibiotics and the peptidase Inhibitors,
Assay for tissue kallikrein activity
Tissue kallikrein activity was assessed by the colorimetric
measurement of the release of 4-nitroaniline (l 9). Twenty iiiicn>
Ihres of Standard (0.1, 0.25, 0.5, l, 2, 4, 8 mU porcine tissue kalli-
krein, Sigma) or sample were diluted in a total volume of 150 μΐ
(0.1 mol/1 Tris, 0.234 mol/l NaCl, pH 7.8). Assays were performed
using 96-well titre plates (Falcon, Heidelberg, Germany). The en-
zymatic reaction was started by addition of 150 μΐ of 0:5 mmol/1
D-Val-cyclohexyl-Ala-Arg-4-nitraniline (Chromozym GK, Boeh-
ringer, Germany) in ie presence and absence.of 200 klU aprotinin
(Bayer AG). The absorbance at 405 nm (Titertek MCC 340; Laus-
anne, Switzerland) was measured to determine the 4-nitroaniline
felease after l, 2, 3, and 6 hours. Tissue kallikrein activity was
calculated from the maximal slope of 4-nitroaniline generation.
One mU porcine tissue kallikrein (Sigma) indueed an increase of
ΔΑ405ηιη/10 min = 0.052 ± 0.005 (n = 12). Orily the activity of
the reaction inhibited by aprotinin was attributed to tissue kalll·
krein-like activity. » i
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Kinin radioimmunoassay
Immunoreactive kinins were measured by a radioimmunoassay
(RIA) described previously (15,20). The detection limit of the RIA
was 20 ng per litre cel] supernatant medium. The inter- and intra-
assay coefficients of Variation were 4% and 5%, respectively. The
antiserum does not distinguish between lysyl-bradykinin (kallidin),
bradykinin and methionyl-lysyl-bradykinin. The cross reactivity
was less than 1% to des-9arg-bradykinin. The peptidase inhibitors
added to the incubation medium did not interfere with the RIA at
the concentrations used in the experiments. No cross reactivity of
the bradykinin-antiserum to porcine tissue kallikrein was observed.
Calculal ions and statistics
Each experiment was done with duplicate or triplicate dishes. Re-
sults are shown äs means ± SEM (n = number of experiments).
CeJl numbers were separately counted in each experiment in one
representative dish. Kinin concentrations measured in the homo-
genates were referred to l O6 endothelial cells. Statistical signifi-
cance was analysed by the Mann-Whitney-\J test for unpaired
samples. P values less than 0.05 were accepted äs statistically sig-
nificant.
Results
1. Immunosta ining of tissue kallikrein
The presence of tissue kallikrein immunoreactivity was
demonstrated by immunostaining. The endothelial cells
from umbilical veins labelled with the anti-human käl-
likrein antibody appeared red; between 55 and 78% of
cells showed a positive staining (n = 5, fig. 1). The
staining of endothelial cells from human pulmonary ar-
teries demonstrated tissue kallikrein immunoreactivity
in 65—75% of the cells (n = 3). Control staining with
sefum instead of the specific antibody resulted in no
specific phosphatase reactioris. Between 85 and 95% of
cells (n = 3) gave a positive staining reaction with fac-





Fig. l Immunohistological detection of tissue 'kallikrein:
a) light mierograph öf endothelial cells frora human umbilical
veins stained with an antHissue kallikrein antibody;
b) control staining without first antibody (Haematoxylin stain,
magnification X 110).
2. Enzymatic activity of tissue kallikrein in
endothelial cells
Kallikrein enzyme activity in cell homogenates of endo-
thelial cells from human umbilical veins was detected by
the cleavage of D-Val-cyclohexyl-Ala-Arg-4-nitraniline.
The total activity was determined äs 5.0 ± 1.1 mU/106
cells (n = 8), the activity inhibited by aprotinin, attri-
buted to tissue kallikrein-like activity, was 3.57 ± 0.47
mU/106 cells in endothelial cells from human umbilical
veins. In endothelial cells from human pulmonary arter-
ies the total activity was 11.2 ± 1.2 mU/106 cells, and
the tissue kallikrein-like activity was 7.52 ± 0.82 mU/
l O6 cells (n = 4, p < 0.01 vs. endothelial cells from hu-
man umbilical veins).
3. Kinin release into supernatants
In the presence of the angiotensin converting enzyme-
inhibitor, lisinopril, and the neutral endopeptidase 24.11-
inhibitor, phosphoramidon, the following kinin-concen-
trations were measured: 10 minutes 40 ± 18 ng/1, l hour
52 ± 23 ng/1, 4 hours 35 ± 15 ng/1 (n = 9 at each time
point). No immunoreactive kinins were detected in the
incubation medium alone, or in supernatants without the
peptidase inhibitors, at all time points (n = 6).
4. Kinin release in endothelial cells from
human umbil ical veins
No immunoreactive kinins were detected after homo-
genisation of cells in the absence of the peptidase inhibi-
tors, lisinopril and phosphoramidon. In the presence of
both inhibitors, kinin contents of 424 ± 83 pg/106 cells
(n = 8) were measured directly after homogenisation.
After 5 minutes, the kinin concentration increased
further to 627 ± 57 pg/106 cells (n = 8) and remained
nearly unchanged during 30 minutes. The presence of
the tissue kallikrein inhibitor, aprotinin (1000 klU/dish),
resulted in significantly lower concentrations at all time
points (P < 0.05 vs. control). Treatment of the cells with
100 mg/1 dextran sulphate reduced the cellular kinin
content from 424 ± 83 pg/106 cells to 102 ± 14 pg/106
cells (n = 8, p < 0.01). After 5 and 30 minutes, the ki-
nin concentrations increased further to 150 ± 23 pg/106
cells (n = 8) and 186 ±31 pg/106 cells (n = 8,
p < 0.05 to 0 minutes; fig. 2a).
Addition of 5 mU tissue kallikrein immediately after
homogenisation resulted in a fivefold increase during
the first 5 minutes up to 2575 ± 400 pg/106 cells (n = 6,
p < 0.01), which declined during the following 25 mi-
nutes (fig. 3).
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Fig. 2 Cellular kinin concentrations immediately after homogeni-
sation and 5 and 30 minutes later in
a) endothelial cells from human umbilical veins, and in
b) endothelial cells from human pulmonary arteries.
Controls (filled circles), endothelial cells treated with dextran sul-
phate (100 mg/1) before homogenisation (open triangles), and cells










Fig. 3 Cellular kinin concentrations in endothelial cells from hu-
man umbilical veins immediately after homogenisation and 5 and
30 minutes after addition of 0.5 mU porcine kallikrein (open trian-
gles) and 5 mU tissue kallikrein (filled triangles), compared with
controls without kallikrein addition (filled circles) (n = 9 each
* P < 0.05 vs. control).
5. Kinin release in endothelial cells from
human pulmonary arteries
Similar experiments were performed with endothelial
cells derived from the human pulmonary artery. In
homogenates of endothelial cells from human pulmon-
ary arteries, no immunoreactive kinins were detected
without the peptidase inhibitors. In the presence of lisin-
opril and phosphoramidon, kinin Contents of 576 ± 146
pg/106 cells (n = 4) were detected immediately after
homogenisation. After 5 and 30 minutes, the kinin con-
centration significantly increased to 857 ± 106 pg/106
cells and 1117 ±165 pg/106 cells (n = 4, flg. 2, left
panel), and was unchanged after 60 mintes (960 ± 60
pg/106 cells, n = 4, not shown in fig. 2). As in endo^·
thelial cells from human umbilical veins, the release of
kinins was reduced in the presence of aprotinin. The
kinin concentrations remairied unchanged 30 minutes
after homogenisation. Treatment of the cells with dex-
tran sulphate significantly decreased cellular kinin con-
centrations (155 ± 28 pg/100' cells, n =? 4, p < 0.05).
The kinin concentrations increased after 5 miriütes to
305 ± 124 pg/106 cells and after 30 minutes to 500
± 245 pg/106 cells (n = 4, fig. 2b),
Discüssion
The present data provide immunohistologicäl and func-=
tiqnal evidence for the presence of tissue kallikrein in
cultured endothelial cells from human umbilical veins
and pulmonary arteries. About two thirds of the endo-
thelial cells from umbilical veins and pulmonary arteries
showed positive staining after immunostaining with a
highly specific antiserum against tissue kallikreiii (18).
The control staining with the endothelial marker (factor
VIII related antigeii) was positive in nearly all the cells.
This confirmed that the tissue kallikrem-immunoreactiv-
ity can be attributed to human endothelial cells. The tis-
sue kallikrein antigen was not found in all the cells,
possibly because low quantities of kallikrein are present,
or the staining technique has low sensitivity. We ob-
served a similar pattern of positive and negative cells in
human smooth musele cells (21). As reported pfeviously
by various authors (9—13), tissue kallikrein is present
in vascular smooth musele cells. Therefore, the apparent
abserice of immunoreactivity in some endothelial cells
may be due to a methodological problem. In all experi-
ments the majority of the endothelial cells were positive
for tissue-kallikrein immunoreactivity.
Tissue kallikrein-like activity was measured by a well
characterised colorirnetric assay (19). Since the speci-
ficity of chromogenic Substrates is not very high, we
performed parallel measürements in the presence of the
tissue kallikrein inhibitor, aprotinin, to exclude major
unspecific protease activity, including plasma kallikrein.
Aprotinin blocked more than 75% of the total enzymatic
activity in endothelial cells. These results might indicate
that the major kininogenase activity in endothelial cell
can be attributed to a tissue kallikrein-like enzyme.
Kinins are generated by enzymatic cleavage of high
molecular weight kininogen $nd low molecular weight
kininogen by kallikreins. Both kininogens are syn-
thesised in the liver and are found.iri plasma. High mol-
ecular rnass kininogen binding sites have been detected
on cultured endothelial cells (22, 23). A recently pub- -
lished study shows binding of high molecular mass kini-
nogen to the eridotheliurri of human umbilical veins in
situ and the generation of bndykinin from the receptor-
i
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bound high molecular weight kininogen after addition
of plasma kallikrein (24). Therefore, it seems likely that
high molecular weight kininogen is the major Substrate
of the endothelial kinin generation. Van Iwaarden et al.
(22) reported that treatment of endothelial cells with
dextran sulphate completely removed the receptor-
bound high molecular weight kininogen. In our experi-
ments, an approximately 75% reduction of kinin release
in endothelial cells from human umbilical veins and en-
dothelial cells from human pulmonary arteries occurred
after washing with dextran sulphate. This indicates that
the main source of kininogen is receptor-bound extra-
cellular kininogen. Only the minor part of kininogen ap-
pears to be localized intracellularly. Whether intracellu-
lar kininogen is synthesised by endothelial cells or de-
rives from serum or plasma is controversely discussed
in various reports (22—24). In our study the intracellular
kinin concentrations measured immediately after hom-
ogenisation were within the ränge of concentrations
causing physiological responses like vasodilatation (l,
2, 6) and were 8 to 10 fold higher than the kinin concen-
trations found in the supernatants. We measured a
further increase of kinin generation in endothelial cells
during the following 30 mimites after homogenisation.
The increase of kinin generation during this time can be
explained by further cleavage of kininogen by cellular
proteases, including kallikreins. Parallel incubation with
the protease inhibitor, aprotinin, an inhibitor of tissue
kallikrein, reduced cellular kinin concentrations and
abolished the increase of kinins in the homogenates dur-
ing this time period, süggesting a role for tissue kalli-
krein in endothelial kinin formation.
Since human umbilical vein endothelial cells are often
considered to be embryonic cells, which inight be differ-
ent from adult phenotypes, we performed parallel
experiments with adult endothelial cells derived from
Segments of the pulmonary artery. We obtairied similar
results for the measurement of tissue kallikrein-like ac-
tivity and cellular kinin formation in endothelial cells
from the pulmonary circulätion, which confirms the re-
sults of the experiments with endothelial cells from hu-
man umbilical veins. Pifferent amounts of kallikrein-
like activity were measured in endothelial cells from hu-
man umbilical veins and endothelial cells from human
pulmonäry arteries. It has been reported before that tis-
sue-like kallikrein activity varies in homogenates from
different human vessels (12).
The present data demonstrate that certain requirements
have to be met to measure kinin formation and release
from endothelial cells. The most important condition is
the Inhibition of bradykinin degrading enzymes. The
most potent of these is angiotensin converting enzyme
(2). Another kininase II, the neutral endopeptidase
24.11, is also involved in the degradation of bradykinin
(25). Intra- and extracellular kinins were only detected
when both enzymes had been blocked by inhibitors. The
second requirement is the exogenous supply of kinin-
ogen (22, 24), which is normally present in cell culture
medium. Whether disintegration (like homogenisation)
of the cells is a requirement for kinin release is not sure.
However, we measured much higher concentrations of
kinins in homogenates than in supernatants. Present data
from different studies (6, 8, 25) indicate that physiologi-
cal Stimuli like flow, shear stress or ischaemia might be
a Stimulus for local kinin release.
A recent publication by Wang and colleagues provides
evidence that tissue kallikrein is a powerfull modulator
of blood pressure in vivo (26). Transgenic mice carrying
the human tissue kallikrein gene demonstrated hypo-
tensive blood pressure, when tissue kallikrein was over-
expressed in tissues and serum. Recent cloning of hu-
man tissue kallikrein gene and its transcripts from colon
(27) might provide the basis for detailed investigation
of tissue kallikrein expression in endothelial cells in the
near future.
In the present study we demonstrated that tissue kalli-
krein is present in human endothelial cells derived from
umbilical veins and pulmonary arteries, and that it con-
tributes to local kinin formation in vitro.
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